Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
A decade after it was founded as a wholly-owned subsidiary of theMultidisciplinary Association for Psychedelic Studies (MAPS), MAPS Public Benefit Corporation has securedover $100 million in a Series A private stock sale. The funds will support the final stages of its application for regulatory approval to sell MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder (PTSD).
MAPS has incubated the only psychedelic-assisted therapy research program that has completed two successful Phase 3 studies and submitted a New Drug Application...
Login or create a forever free account to read this news
Sign up/Log in